Daiichi Sankyo and partner AstraZeneca’s Enhertu previously wowed industry watchers with stellar clinical data in heavily pretreated breast cancer, leading to a speedy FDA nod at the end of 2019.

The antibody-drug conjugate (ADC) market is emerging as one of the most competitive areas in pharma, with companies such as AstraZeneca, Gilead and Pfizer investing billions into the space. | The ...

Parsippany-based Daiichi Sankyo Inc. announced Monday that Sharp Packaging Services, a division of UDG Healthcare plc, has purchased the Daiichi pharmaceutical packaging plant located in Bethlehem ...

U3 Pharma’s preclinical anticancer agents will strengthen Daiichi Sankyo’s focus on this indication. Daiichi Sankyo is taking over U3 Pharma for €150 million, or about $236.22 million. U3 ...

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality ...

TOKYO and LONDON Daiichi Sankyo has agreed to purchase the German biotech company U3 Pharma for $233.5 million, in an effort to boost its cancer drug pipeline, according to Reuters.

Japan's Daiichi Sankyo Company Ltd <4568.T> is selling shares worth up to $3.6 billion in Indian drugmaker Sun Pharmaceutical Industries Ltd <SUN.NS>, setting it on course to retreat from India ...

Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO Provided by Business Wire May 22, 2025, 2:00:00 PM ...

Daiichi Sankyo Company, Limited announced that at the meeting of the board of directors held on October 31, 2023, the company passed a resolution on the basic policy for carrying out an ...

Daiichi Sankyo said today it has sold off the 8.9% stake in Sun Pharmaceutical Industries it inherited when Sun Pharma agreed to buy Ranbaxy from Daiichi Sankyo last year.

Australia&nbsp;biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant ...

Mumbai-headquartered Sun Pharma, India's largest drugmaker by sales, agreed to buy Ranbaxy from Daiichi Sankyo for $3.2 billion in April 2014 .